Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial by Sharma, Padmanee, Prof, Callahan, Margaret K, MD, Bono, Petri, MD, Kim, Joseph, MD, Spiliopoulou, Pavlina, MD, Calvo, Emiliano, MD, Pillai, Rathi N, MD, Ott, Patrick A, MD, de Braud, Filippo, Prof, Morse, Michael, Prof, Le, Dung T, MD, Jaeger, Dirk, MD, Chan, Emily, MD, Harbison, Chris, PhD, Lin, Chen-Sheng, PhD, Tschaika, Marina, MD, Azrilevich, Alex, PharmD, Rosenberg, Jonathan E, MD

Get full text

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial by Antonia, Scott J, Prof, López-Martin, José A, MD, Bendell, Johanna, MD, Ott, Patrick A, MD, Taylor, Matthew, MD, Eder, Joseph Paul, MD, Jäger, Dirk, MD, Pietanza, M Catherine, MD, Le, Dung T, MD, de Braud, Filippo, Prof, Morse, Michael A, Prof, Ascierto, Paolo A, MD, Horn, Leora, MD, Amin, Asim, MD, Pillai, Rathi N, MD, Evans, Jeffry, Prof, Chau, Ian, MD, Bono, Petri, MD, Atmaca, Akin, MD, Sharma, Padmanee, Prof, Harbison, Christopher T, PhD, Lin, Chen-Sheng, PhD, Christensen, Olaf, MD, Calvo, Emiliano, Dr

Get full text

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 d... by Fizazi, Karim, Prof, Massard, Christophe, MD, Bono, Petri, MD, Jones, Robert, MD, Kataja, Vesa, Prof, James, Nicholas, Prof, Garcia, Jorge A, MD, Protheroe, Andrew, MD, Tammela, Teuvo L, Prof, Elliott, Tony, MD, Mattila, Leena, MD, Aspegren, John, MSc, Vuorela, Annamari, PhD, Langmuir, Peter, MD, Mustonen, Mika, PhD

Get full text

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib... by Cortés, Javier, Dr, Dieras, Véronique, MD, Ro, Jungsil, MD, Barriere, Jérôme, MD, Bachelot, Thomas, MD, Hurvitz, Sara, MD, Le Rhun, Emilie, MD, Espié, Marc, MD, Kim, Sung-Bae, MD, Schneeweiss, Andreas, MD, Sohn, Joo Hyuk, MD, Nabholtz, Jean-Marc, Prof, Kellokumpu-Lehtinen, Pirkko-Liisa, Prof, Taguchi, Julie, MD, Piacentini, Federico, MD, Ciruelos, Eva, MD, Bono, Petri, MD, Ould-Kaci, Mahmoud, MD, Roux, Flavien, MSc, Joensuu, Heikki, Prof

Get full text

Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial by Joensuu, Heikki, Prof, Kellokumpu-Lehtinen, Pirkko-Liisa, Prof, Huovinen, Riikka, MD, Jukkola-Vuorinen, Arja, MD, Tanner, Minna, MD, Asola, Raija, MD, Kokko, Riitta, MD, Ahlgren, Johan, MD, Auvinen, Päivi, MD, Hemminki, Akseli, Prof, Paija, Outi, MD, Helle, Leena, MD, Nuortio, Lauri, MD, Villman, Kenneth, MD, Nilsson, Greger, MD, Lahtela, Sirpa-Liisa, MD, Lehtiö, Kaisa, MD, Pajunen, Marjo, MD, Poikonen, Paula, MD, Nyandoto, Paul, MD, Kataja, Vesa, MD, Bono, Petri, MD, Leinonen, Mika, MSc, Lindman, Henrik, MD

Get full text

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial by Eisen, Tim, Prof, Joensuu, Heikki, Prof, Nathan, Paul D, PhD, Harper, Peter G, FRCP, Wojtukiewicz, Marek Z, Prof, Nicholson, Steve, MD, Bahl, Amit, MD, Tomczak, Piotr, PhD, Pyrhonen, Seppo, Prof, Fife, Kate, MD, Bono, Petri, PhD, Boxall, Jane, RN, Wagner, Andrea, MD, Jeffers, Michael, PhD, Lin, Tiffany, PharmD, Quinn, David I, FRACP

Get full text